Skip to main content
Midas Edge

Datavault AI Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

DVLT$0.06+3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

For the three and nine months ended September 30, 2025 and 2024

​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Convertible Preferred Stock · ​ · ​ · Common Shares · ​ · Additional · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Shares · Amount · Paid-in Capital · Deficit · Equity
Balance as of December 31, 2024—​$—​52,034,060​$5​$384,172​$(298,451)​$85,726
Stock-based compensation​—​​—​​5,986,893​​—​​648​​—​​648
Issuance of common stock in connection with the February Offering​—​​—​​4,757,126​​1​​4,859​​—​​4,860
Issuance of common stock in connection with warrant exercise—​—​3,246,111​—​—​—​—
Conversion of liability warrants to equity warrants​—​​—​​—​​—​​15​​—​​15
Net loss​—​​—​​—​​—​​—​​(9,563)​​(9,563)
Balance as of March 31, 2025​—​​—​​66,024,190​$6​$389,694​$(308,014)​$81,686
Stock-based compensation​—​​—​​3,701,197​​—​​1,151​​—​​1,151
Issuance of common stock in connection with warrant exercise​—​​—​​2,989,887​​—​​—​​—​​—
Issuance of common stock for conversions of 2025 Notes​—​​—​​1,845,945​​—​​1,545​​—​​1,545
Issuance of common stock with NYIAX transaction​—​​—​​1,500,000​​—​​—​​—​​—
Issuance of warrants with the 2025 Notes​—​​—​​—​​—​​16,657​​—​​16,657
Issuance of common stock for the acquisition of CSI​—​​—​​10,600,000​​1​​10,282​​—​​10,283
Equity issuance costs​—​​—​​—​​—​​(137)​​—​​(137)
Net loss​—​​—​​—​​—​​—​​(37,116)​​(37,116)
Balance as of June 30, 2025—​​—​86,661,219​$7​$419,192​$(345,130)​$74,069
Stock-based compensation​—​​—​​1,253,313​​—​​2,591​​—​​2,591
Issuance of common stock for the 2025 notes and Q3 notes conversions​—​​—​​95,506,855​​10​​33,213​​—​​33,223
Issuance of common stock in connection with Scilex investment​—​​—​​15,000,000​​2​​7,836​​—​​7,838
Issuance of common stock in connection with EOS conversion​—​​—​​10,000,000​​1​​3,099​​—​​3,100
Issuance of common stock for the acquisition of intangible assets​—​​—​​5,500,000​​1​​3,484​​—​​3,485
Exchange of warrants for common stock with the 10% notes extinguishment​—​​—​​—​​—​​3,665​​—​​3,665
Shares issued in connection with NYIAX transaction​—​​—​​3,280,000​​1​​4,893​​—​​4,894
Equity issuance costs​—​​—​​—​​—​​(381)​​—​​(381)
Net loss​—​​—​​—​​—​​—​​(32,976)​​(32,976)
Balance as of September 30, 2025—​​—​217,201,387​$22​$477,592​$(378,106)​$99,508
​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Convertible Preferred Stock · ​ · ​ · Common Shares · ​ · Additional · ​ · Accumulated · ​ · Stockholders’
​ · Shares · ​ · Amount · Shares · Amount · Paid-in Capital · Deficit · Equity (Deficit)
Balance as of December 31, 2023​38,335​$247​​222,380​$1​$241,884​$(247,042)​$(5,157)
Stock-based compensation​—​​—​​4​​—​​380​​—​​380
Cumulative effect of ASU 2020-06 adoption​—​​116​​—​​—​​(116)​​—​​(116)
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts​29,322​​386​​—​​—​​—​​—​​-
Issuance of common stock in connection with conversion of Series B preferred stock​(5,000)​​(325)​​8,038​​—​​325​​—​​325
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock​—​​5,842​​—​​—​​(5,842)​​—​​(5,842)
Repurchase of Series B preferred stock and Series B preferred stock warrants​(62,657)​​(6,266)​​—​​—​​824​​—​​824
Issuance of common stock, pre-funded units and warrants, net of offering costs​—​​—​​1,442,518​​—​​4,210​​—​​4,210
Issuance of common stock in connection with reverse split rounding-up for fractional shares​—​​—​​84,255​​—​​—​​—​​-
Net income​—​​—​​—​​—​​—​​2,707​​2,707
Balance as of March 31, 2024—​​—​​1,757,195​$1​$241,665​$(244,335)​$(2,669)
Stock-based compensation​—​​—​​255,915​​—​​241​​—​​241
Issuance of common stock in connection with warrant exercise​—​​—​​441,822​​—​​556​​—​​556
Issuance of common stock and warrants, net of offering costs​—​​—​​2,466,583​​—​​8,756​​—​​8,756
Issuance of common stock to vendors​—​​—​​—​​—​​360​​—​​360
Restricted stock awards cancelled​—​​—​​(82)​​—​​—​​—​​-
Release of vested restricted common stock​—​​—​​1​​—​​—​​—​​-
Conversion of liability warrants to equity warrants​—​​—​​—​​—​​41,851​​—​​41,851
Net loss​—​​—​​—​​—​​—​​(42,665)​​(42,665)
Balance as of June 30, 2024​—​​—​​4,921,434​$1​$293,429​$(287,000)​$6,430
Stock-based compensation​—​​—​​532,973​​—​​345​​—​​345
Issuance of common stock in connection with warrant amendment​—​​—​​887,356​​—​​—​​—​​-
Issuance of common stock in connection with warrant exercise​—​​—​​1,193,721​​—​​2,372​​—​​2,372
Restricted stock awards cancelled​—​​—​​(3,859)​​—​​—​​—​​-
Issuance of common stock to vendors​—​​—​​236,204​​—​​240​​—​​240
Net loss​—​​—​​—​​—​​—​​(5,092)​​(5,092)
Balance as of September 30, 2024​—​​—​​7,767,829​$1​$296,386​$(292,092)​$4,295
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.